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Ring size in cyclic endomorphin-2 analogs
modulates receptor binding aﬃnity and
selectivity†
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Anna Janecka*a
The study reports the solid-phase synthesis and biological evaluation of a series of new side chain-to-
side chain cyclized opioid peptide analogs of the general structure Tyr-[D-Xaa-Phe-Phe-Asp]NH2, where
Xaa = Lys (1), Orn (2), Dab (3), or Dap (4) (Dab = 2,4-diaminobutyric acid, Dap = 2,3-diaminopropionic
acid), containing 17- to 14-membered rings. The inﬂuence of the ring size on binding to the MOP, DOP
and KOP opioid receptors was studied. In general, the reduction of the size of the macrocyclic ring
increased the selectivity for the MOP receptor. The cyclopeptide incorporating Xaa = Lys displayed sub-
nanomolar MOP aﬃnity but modest selectivity over the KOP receptor, while the analog with the Orn
residue showed increased aﬃnity and selectivity for MOP. The analog with Dab was a weak MOP agonist
and did not bind to the other two opioid receptors. Finally, the peptide with Xaa = Dap was completely
MOP receptor-selective with subnanomolar aﬃnity. Interestingly, the deletion of one Phe residue from 1 led
to the 14-membered Tyr-c[D-Lys-Phe-Asp]NH2 (5), a potent and selective MOP receptor ligand. The in vitro
potencies of the new analogs were determined in a calcium mobilization assay performed in Chinese
Hamster Ovary (CHO) cells expressing human recombinant opioid receptors and chimeric G proteins. A
good correlation between binding and the functional test results was observed. The inﬂuence of the ring
size, solid support and the N-terminal protecting group on the formation of cyclodimers was studied.
Introduction
The study of naturally occurring peptides provides a rational
approach for the design of new drugs. A major goal in opioid
peptide research is the development of novel analgesics which
could replace morphine with its well-known side eﬀects.1 Two
endogenous tetrapeptide ligands of the MOP receptor, endo-
morphin-1 (EM-1, Tyr-Pro-Trp-Phe-NH2) and endomorphin-2
(EM-2, Tyr-Pro-Phe-Phe-NH2),
2 display high antinociceptive
activity in several animal models of acute, inflammatory and
neuropathic pain and are devoid of some serious side eﬀects
of morphine.3,4 However, native opioid peptides have several
limitations, such as poor metabolic stability and inability to
cross the blood–brain barrier (BBB), which distinguish them
as therapeutic agents.5,6
To address these shortcomings of EMs and explore their
structure–activity relationships, a variety of chemical modifi-
cations have been investigated.7–9 One such modification is
cyclization, which is an eﬃcient method to increase resistance
to peptidases and can often be achieved without loss of
activity.10 EMs are diﬃcult to cyclize due to their short
sequence and the lack of reactive side chain groups. Therefore,
to obtain cyclic analogs of EMs various approaches have been
used, such as elongation of their sequence or introduction of
amino acid residues with functionalized side chains. Cardillo
et al. synthesized a library of cyclic analogs of EM-1, contain-
ing a Gly5 bridge between Tyr1 and Phe4 and therefore
deprived of the positively charged Tyr N-terminal amino
group.11 From this library, the cyclopeptide c[Tyr-D-Pro-D-Trp-
Phe-Gly] produced significant antinociception in a visceral
pain model.12
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Mollica et al. replaced Pro2 in the sequence of EM-2 by cis-
4-aminoproline (cAmp), introducing an additional amino
group available for a side chain-to-tail cyclization reaction. The
obtained 11-membered cyclopeptide Tyr-c[cAmp-Phe-Phe] was
highly conformationally restricted, which drastically aﬀected
its binding to the MOP receptor.13 Assigning a diﬀerent stereo-
chemistry to both Phe residues present in the ring led to the
modulation of the opioid receptor aﬃnity.14
In our eﬀort to obtain cyclic EM-2 analogs, we adopted a
side chain-to-side chain approach based on the incorporation
of two bivalent amino acids in positions 2 and 5 of a pentapep-
tide backbone.15,16 Some of the thus obtained cyclic analogs
showed significantly increased activity and bioavailability.
Recently, we used liquid chromatography combined with on-
line mass spectrometry (LC-MS) and tandem mass spec-
trometry (LC-MS/MS) to study the cyclization reaction of EM-2
analogs.17 Cyclization of the pentapeptides Tyr/Dmt-D-Lys-Phe-
Phe-Asp-NH2 (where Dmt = 2′,6′-dimethyltyrosine) through an
amide bond on the MBHA Rink Amide resin resulted in the
formation of cyclic monomers and cyclic but not linear
dimers. The comparison of the cyclic monomer/dimer ratios
for analogs with Tyr versus Dmt in position 1 revealed that the
presence of the exocyclic Dmt favored the formation of the
cyclic monomer, most likely due to the increased steric bulk of
this amino acid side chain, as compared with Tyr.
Here, continuing our structure–activity relationship studies
of EM-2 cyclic analogs, we assessed the influence of the ring
size on the aﬃnity, selectivity and potency of analogs at the
three opioid receptors. Additionally, the impact of the ring size
and the type of a solid-phase support used for the synthesis on
the amount of side-product formation was studied.
Materials and methods
General methods
All reagents, unless otherwise stated, were purchased from
Sigma Aldrich (Poznan, Poland). Protected amino acids were
purchased from Bachem AG (Bubendorf, Switzerland) or
obtained from TriMen Chemicals Ltd (Lodz, Poland). Opioid
radioligands, [3H]DAMGO, [3H][Ile5,6]deltorphin-2 and [3H]nor-
binaltorphimine (nor-BNI) were synthesized in the Biological
Research Centre of Hungarian Academy of Sciences (Szeged,
Hungary). Analytical and semi-preparative RP-HPLC was per-
formed using a Waters Breeze instrument (Milford, MA, USA)
with a dual absorbance detector (Waters 2487) on a Vydac C18
column (5 μm, 4.6 × 250 mm) and a Vydac C18 column (10 μm,
22 × 250 mm), respectively. High resolution mass spectra were
recorded using a Bruker micrOTOF-Q mass spectrometer
(Bruker Daltonics, Bremen, Germany) with electrospray ioniza-
tion (ESI-MS). The instrument was operated in the positive-ion
mode and calibrated with the Tunemix™ mixture (Agilent
Technologies, Palo Alto, CA, USA). For LC-MS analysis, an
Agilent 1200 chromatograph (Agilent Technologies, Palo Alto,
CA, USA) equipped with an Aeris Peptide XB-C18 column
(3.6 µm, 2.1 × 50 mm) (Phenomenex, Torrence, CA, USA) was
used. For LC-MS and LC-MS/MS studies a linear gradient of
10–50% B in A over 25 min was applied (A: 0.1% formic acid in
water, B: 0.1% formic acid in acetonitrile, flow rate 0.1 mL
min−1). 1H-NMR spectra were recorded in DMSO-d6 on a
Bruker Avance II+ 700 MHz spectrometer and the chemical
shifts were reported as δ values relative to residual DMSO (δH =
2.50 ppm) as an internal standard. J values are given in Hz.
Synthesis of peptides
Peptides were synthesized on MBHA Rink-Amide peptide resin
(100–200 mesh, 0.8 mM g−1, Novabiochem) using Fmoc-pro-
tected amino acids.18 The hydroxyl group of Tyr was protected
by a t-Bu group and the hyper-acid labile Mtt/O-2PhiPr groups
were used for the selective D-Lys/D-Orn/D-Dab/D-Dap and Asp
side chain protection, respectively. TBTU was used as a coup-
ling agent. Fully assembled Fmoc-protected peptides were
treated with 1% TFA in DCM to remove side chain protecting
groups (Mtt and O-2PhiPr), followed by the on-resin cyclization
with TBTU. After the removal of a Fmoc group from Tyr, pep-
tides were cleaved from the resin with a TFA/TIS/H2O mixture
(95 : 2.5 : 2.5) for 3 h at room temperature.
Alternatively, MBHA amide peptide resin (100–200 mesh,
0.8 mM g−1, Novabiochem) was used with Boc-protected
amino acids.15 The hydroxyl group of Tyr was protected by
2-Br-Z, while Fmoc was used for the side chain amino group
protection of D-Lys and D-Orn and the β-carboxy group of Asp
was blocked by OFm. 50% TFA in DCM was used for the de-
protection of Boc-groups and TBTU was employed for coup-
ling. Fully assembled Boc-protected peptides were treated with
20% piperidine in DMF to remove base-labile groups (Fmoc
and OFm), followed by cyclization with TBTU. Simultaneous
deprotection of Tyr and cleavage of peptides from the resin
were accomplished by treatment with HBr (33% in AcOH)/TFA/
thioanisole (0.4 : 10 : 0.5) (3 × 30 min) at room temperature.
The crude peptide salts were purified by RP-HPLC using a
linear gradient of 0–100% B over 40 min at the flow rate of
15 mL min−1, with UV detection at 214 nm (injection volume
0.5 mL). Solvents: A: 0.1% TFA in water and B: 0.1% TFA in
acetonitrile/water (80 : 20, v/v). The purity of the final peptides
was verified by analytical RP-HPLC in the same solvent system
over 25 min with the flow rate of 1 mL min−1. The synthesized
compounds were characterized by ESI-MS (Table 1) and
1H-NMR.
Tyr-c[D-Lys-Phe-Phe-Asp]NH2 1
1H-NMR was described
previously.16
Tyr-c[D-Orn-Phe-Phe-Asp]NH2 2 (DMSO-d6) δ: 1.03 (m, 1H),
1.20 (m, 1H), 1.35 (m, 1H), 1.46 (m, 1H), 2.37–2.48 (m, 2H),
2.79–2.85 (m, 3H), 2.87–2.97 (m, 2H), 3.00–3.06 (m, 2H), 3.08
(dd, J = 14.0, J = 7.0, 1H), 4.02 (m, 1H), 4.12 (q, J = 7.7, 1H),
4.26 (m, 1H), 4.42 (q, J = 7.0, 1H), 4.57 (m, 1H), 6.73 (d, J = 8.4,
2H), 7.02–7.27 (m, 12H), 7.86 (d, J = 7.0, 1H), 7.88 (t, J = 6.3,
1H), 7.97 (d, J = 6.3 1H), 8.05 (d, J = 9.1, 1H), 8.13 (bs, 2H), 8.44
(d, J = 7.7, 1H), 9.37 (s, 1H).
Tyr-c[D-Dab-Phe-Phe-Asp]NH2 3
1H-NMR (DMSO-d6) δ: 1.52
(m, 1H), 1.79 (m, 1H), 2.29 (m, 1H), 2.68–2.73 (m, 2H),
2.81–2.86 (m, 2H), 2.96–3.08 (m, 2H), 3.18 (dd, J = 14.0, J = 6.3,
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1H), 3.93 (m, 1H), 4.17 (m, 1H), 4.21 (q, J = 7.7, 1H), 4.37 (m,
1H), 4.46 (m, 1H), 4.55–4.63 (m, 2H), 6.72 (d, J = 8.4, 2H),
6.99–7.29 (m, 12H), 7.48 (t, J = 6.3, 1H), 8.01 (d, J = 7.0, 1H),
8.12 (d, J = 7.7, 1H), 8.36 (bs, 2H), 8.47 (d, J = 7.7, 1H), 9.36
(s, 1H).
Tyr-c[D-Dap-Phe-Phe-Asp]NH2 4
1H-NMR (DMSO-d6) δ: 2.29
(dd, J = 8.4, J = 4.2, 1H), 2.65–2.79 (m, 4H), 2.84 (dd, J = 9.1, J =
4.9, 1H), 2.93–3.06 (m, 2H), 3.27 (m, 1H), 3.75 (m, 1H), 3.97
(m, 1H), 4.03–4.07 (m, 2H), 4.40 (m, 1H), 4.47 (q, J = 6.3, 1H),
6.74 (d, J = 8.4, 2H), 7.04–7.06 (m, 6H), 7.15–7.28 (m, 7H), 7.61
(d, J = 8.4, 1H), 7.64 (dd, J = 7.0, J = 4.9, 1H), 8.16 (bs, 2H), 8.44
(d, J = 8.4, 1H), 8.72 (d, J = 7.0, 1H), 9.39 (s, 1H).
Tyr-c[D-Lys-Phe-Asp]NH2 5
1H-NMR (DMSO-d6) δ: 0.89–0.98
(m, 2H), 1.12–1.24 (m, 2H), 1.34 (m, 1H), 1.45 (m, 1H), 2.30
(dd, J = 14.7, J = 11.9, 1H), 2.44 (dd, J = 14.0, J = 2.8, 1H), 2.68
(dd, J = 14.0, J = 7.0, 1H), 2.76 (m, 1H), 2.82–2.93 (m, 2H), 3.06
(dd, J = 14.0, J = 7.7, 1H), 3.43 (m, 1H), 3.94 (m, 1H), 4.07 (m,
1H), 4.59–4.55 (m, 2H), 6.72 (d, J = 9.0, 2H), 7.01 (d, J = 9.0,
2H), 7.15–7.17 (m, 3H), 7.22–7.24 (m, 2H), 7.47 (d, J = 8.4, J =
35, 1H), 7.78 (t, J = 7.0, 1H), 7.79 (t, J = 8.4, 1H), 8.11 (bs, 2H),
8.17 (d, J = 7.0, 1H), 9.36 (s, 1H).
Determination of monomer/dimer ratios
The crude products were subjected to LC-MS analysis to deter-
mine the monomer/dimer (M/D) ratio. LC-MS chromatograms
were analysed using Bruker Compass Data Analysis 4.0 soft-
ware by extracting the traces of chromatograms for expected
m/z values for protonated product ions (XIC). The peaks were
identified by analysis of mass spectra representing the selected
LC-MS signals and confirmed by additional MS/MS and
LC-MS/MS experiments. The obtained chromatograms were
integrated and the peak areas were compared to obtain the
M/D ratio.
Opioid receptor binding assays
The receptor binding assays were performed according to the
modified method described by Misicka et al.19 Binding
aﬃnities for all three opioid receptors, MOP, DOP and KOP,
were determined by displacing, respectively, [3H]DAMGO and
[3H][Ile5,6]deltorphin-2 from Wistar rat brain membrane
binding sites and [3H]nor-BNI from guinea pig brain mem-
branes. Briefly, crude membrane preparations were incubated
at 25 °C for 120 min with appropriate concentrations of a
tested peptide in the presence of 0.5 nM radioligand in a total
volume of 0.5 mL of 50 mM Tris/HCl (pH 7.4) containing
bovine serum albumin (BSA) (1 mg mL−1), bacitracin (50 μg
mL−1), bestatin (30 μM) and captopril (10 μM). Non-specific
binding was determined in the presence of 1 μM naloxone.
Incubations were terminated by rapid filtration through the
GF/B Whatman (Brentford, UK) glass fiber strips (pre-soaked
for 2 h in 0.5% (v/v) polyethylamine) using Millipore Sampling
Manifold (Billerica, USA). The filters were washed three times
with 4 mL of ice-cold Tris buﬀer solution. The bound radio-
activity was measured in a Packard Tri-Carb 2100 TR liquid
scintillation counter (Ramsey, MN, USA) after overnight extrac-
tion of the filters in 4 mL of a Perkin Elmer Ultima Gold scin-
tillation fluid (Wellesley, MA, USA). Three independent
experiments for each assay were carried out in duplicate. The
data were analyzed by a nonlinear least squares regression ana-
lysis computer program, GraphPad PRISM 5.0 (GraphPad Soft-
ware Inc., San Diego, U.S.A.).
Calcium mobilization assay
Chinese Hamster Ovary (CHO) cells stably co-expressing
human recombinant MOP or KOP and the C-terminally modi-
fied Gαqi5 and CHO cells co-expressing the human recombi-
nant DOP receptor and the GαqG66Di5 chimeric protein were
generated as previously described.20–22 Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM)/HAMS F12
(1 : 1) supplemented with 10% fetal calf serum, penicillin
(100 IU mL−1), streptomycin (100 mg mL−1), geneticin (G418;
200 µg mL−1) and hygromycin B (100 µg mL−1) and kept at
37 °C in a 5% CO2/humidified air. When confluence was
reached (3–4 days), cells were sub-cultured using trypsin/EDTA
and used for the assay.
Cells were seeded at a density of 50 000 cells per well into
96-well black, clear-bottom plates. After 24 h incubation, the
cells were loaded with Hank’s Balanced Salt Solution (HBSS)
supplemented with 2.5 mM probenecid, 3 µM of the calcium
sensitive fluorescent dye Fluo-4 AM, 0.01% pluronic acid and
20 mM HEPES (pH 7.4) for 30 min at 37 °C. The loading solu-
tion was aspirated and cells were washed with 100 µL per well
Table 1 Analytical data of novel cyclic analogs
No. Sequence
m/z [M + H]+
Monomer (%) Dimer (%) M/D ratio Ring sizeCalcd Obsda
1 Tyr-c[D-Lys-Phe-Phe-Asp]NH2 700.345 700.342 70.26 29.74 2.36 17
2 Tyr-c[D-Orn-Phe-Phe-Asp]NH2 686.330 686.338 49.76 50.24 0.99 16
3 Tyr-c[D-Dab-Phe-Phe-Asp]NH2 672.314 672.309 80.88 19.12 4.23 15
4 Tyr-c[D-Dap-Phe-Phe-Asp]NH2 658.298 658.299 53.25 46.75 1.14 14
5 Tyr-c[D-Lys-Phe-Asp]NH2 553.277 553.281 27.72 72.27 0.38 14
1a Tyr-c[D-Lys-Phe-Phe-Asp]NH2 700.345 700.354 96.01 3.99 24.06 17
2a Tyr-c[D-Orn-Phe-Phe-Asp]NH2 686.330 686.330 99.70 0.30 332.33 16
aMonoizotopic mass observed by ESI MS+ ionization.
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of HBSS, HEPES (20 mM, pH 7.4), 2.5 mM probenecid and
500 µM Brilliant Black. Then 100 µL per well of the same
buﬀer was added. Peptides were dissolved in 1% DMSO in bi-
distilled water at a final concentration of 1 mM. The successive
dilutions were made in the HBSS/HEPES (20 mM) buﬀer (con-
taining 0.005% BSA fraction V).
After placing both plates (cell culture and compound plate)
into the FlexStation II, the on-line additions were carried out
in a volume of 50 µL per well and fluorescence changes were
measured at 37 °C.
Agonist potencies are given as pEC50 that is the negative
logarithm of the molar concentration of an agonist that pro-
duces 50% of the maximal possible eﬀect. Concentration–
response curves were fitted with the four parameter logistic
nonlinear regression model
Effect ¼ baselineþ Emax  baseline
1þ 10ðlog EC50XÞn
where X is the agonist concentration and n is the Hill coeﬃ-
cient. Ligand eﬃcacy was expressed as intrinsic activity (α) cal-
culated as the ratio of Emax of the ligand to Emax of the
standard agonist. At least four separate experiments were per-
formed in duplicate. Curve fittings were performed using
GraphPad PRISM 5.0 (GraphPad Software Inc., San Diego,
U.S.A.). Data have been statistically analyzed with one way
ANOVA followed by the Dunnett’s test for multiple compari-
sons; p values less than 0.05 were considered to be significant.
Molecular dynamics simulations
Molecular dynamics (MD) simulations were performed using
the AMBER force field in a 30 × 30 × 30 Å box of standard
TIP3P water for 10 ns at 298 K.23–25 Periodic boundary con-
ditions were applied at constant temperature and pressure
(Berendsen scheme, a bath relaxation constant of 0.2).26 A
dielectric constant of 1 was used and the cut-oﬀ distance for
the non-bonded interactions was 12 Å. All water molecules
with atoms that come closer than 2.3 Å to a solute atom were
eliminated. For 1–4 scale factors, van der Waals and electro-
static interactions were scaled in AMBER to half their nominal
value. The integration time step was set to 0.1 fs. The system
coordinates were collected every picosecond.
Results and discussion
Influence of the resin type and N-terminal protection on
dimer formation
All peptides were synthesized by the conventional solid-phase
procedure on the MBHA Rink Amide resin, using techniques
for Fmoc-protected amino acids with the hyper-acid labile Mtt/
O-2PhiPr groups for the selective amine/carboxyl side chain
protection of the basic amino acids and Asp, respectively, that,
after deprotection, would enable on-resin cyclization.27,28 For
comparison, analogs 1 and 2 were re-synthesized on the
MBHA Amide resin using the Boc strategy with Fmoc and OFm
groups for the selective amine/carboxyl side chain protection
of D-Lys/D-Orn and Asp, respectively.
High resolution mass spectrometry (LS-MS and MS/MS)
experiments confirmed the identity of all the synthesized pep-
tides. RP-HPLC analyses of the final purified products indi-
cated a purity of 97% or greater (Table 1).
The LC-MS chromatograms were examined to obtain the
extracted ion chromatograms (XIC) for calculated m/z values of
protonated peptides 1–5. In the case of the Fmoc-based pro-
cedure (peptides 1–5) there were two peaks corresponding to
the expected m/z values in the respective chromatograms. The
mass spectra corresponding to these peaks revealed diﬀerent
distributions of isotopic peaks, characteristic of the single
charge (+1) ions (for the faster eluting compounds) and
double charge (+2) ions (for the slower eluting compounds).
Therefore, the calculated molecular masses indicated the
monomeric and dimeric compositions of these forms of pep-
tides. The energy required for fragmentation in collision
induced dissociation experiments (CID MS/MS), as well as the
analysis of MS/MS spectra confirmed the dimeric character of
the second cyclic product. The LC-MS and MS/MS procedures
for the identification of the dimeric form of peptides were dis-
cussed in detail previously.17
The M/D ratios in the crude mixtures of peptides 1–4 of a
general structure Tyr-c[D-Xaa-Phe-Phe-Asp]NH2, where Xaa was
Lys, Orn, Dab or Dap, synthesized by the Fmoc-strategy, varied
from 0.99 to 4.23 and depended on the size of the ring
(Table 1). However, a straightforward relationship between the
dimer amount and the ring size was not observed. The peptide
incorporating the Dab residue (15-membered ring) contained
about 81% of the desired monomer in the crude mixture, the
analog with Lys (17-membered ring) about 70%, while the
cyclic analogs with Orn and Dap residues (16 and 14-mem-
bered rings, respectively) were formed in only about 50% yield.
It seems that an uneven number of atoms forming the ring
favored monomer formation.
Another interesting observation was that in the case of
analogs 4 and 5, both containing 14-membered rings, diﬀerent
amounts of monomers were formed (53.25 and 27.72%,
respectively). The diﬀerence between these two analogs is that
5 is a tetrapeptide incorporating the Lys residue with its long
side chain, while 4 is a pentapeptide incorporating a short
side chain Dap. It seems that the amino group at the end of a
flexible 4-carbon side chain of Lys can easily reach the
β-carboxyl of Asp of a neighboring peptide forming a dimer.
On the other hand, a short, more rigid side chain of Dap is
less likely to form intramolecular bonds and favors monomer
formation.
Analogs 1 and 2 were then re-synthesized on the MBHA
Amide resin using the Boc strategy (peptides 1a and 2a). In
this case, the monomeric forms dominated in LC-MS chroma-
tograms. A thorough search revealed that the dimeric forms
were also present but the intensities of XIC peaks were below
the standard selection limit of the software and manual selec-
tion and integration of peaks was required to obtain the data
for ratio calculations. Fig. 1 presents the exemplary LC-MS
Paper Organic & Biomolecular Chemistry
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chromatograms of crude peptide 2 synthesized on the MBHA
Rink Amide and MBHA Amide resins.
The diﬀerence between MBHA Rink Amide and MBHA
Amide resins is that in the first one the active NH2 group is
moved away from the resin by a long spacer, while in the
second the NH2 group is situated much closer to the solid
support. Therefore, it could be speculated that the steric hin-
drance caused by the proximity of the MBHA Amide resin
surface prevents the formation of intramolecular bonds. For
dimer formation, an antiparallel orientation of peptide chains
is required, which supports the demand for a flexible linker.
Yet another aspect that should be taken into consideration
when the amount of dimer formation is discussed is the pres-
ence of diﬀerent protecting groups (Fmoc or Boc) on the exo-
cyclic Tyr residue during cyclization. It could be speculated
that these protecting groups may enforce diﬀerent confor-
mations of a peptide chain which either favor dimerization or
make it almost impossible.
Biological studies
Opioid receptor binding studies. Opioid binding aﬃnities
of cyclic analogs 1–5 for the MOP, DOP and KOP receptors
were determined by radioligand competition analysis using
[3H]DAMGO, [3H][Ile5,6]deltorphin-2 and [3H]nor-BNI, respect-
ively. These data, calculated as IC50 values, are summarized in
Table 2. Pentapeptides 1 and 2 exhibited subnanomolar
aﬃnity for MOP and nanomolar for KOP, while 3 and
especially 4 were MOP selective. Analogs 2–4 did not bind to
DOP while 1 showed a weak aﬃnity for this receptor. Com-
pound 5 is a cyclic tetrapeptide with only one Phe residue and
cannot be considered an EM-2 analog. Nevertheless, this
analog showed very high aﬃnity for MOP and weak aﬃnity for
the other two opioid receptors. It seems that the binding
pocket of the MOP receptor can accommodate a variety of
ligands.
Functional assay
The pharmacological profiles of analogs 1–5 were character-
ized in vitro at all three opioid receptors in the calcium mobili-
zation assay.22 The calculated agonist potencies (pEC50) and
eﬃcacies (α) of the analogs are summarized in Table 3. EM-2,
DPDPE, and dynorphin A were used as the reference agonists
Table 2 Opioid receptor binding data of the cyclic analogsa
No. Sequence
IC50
b [nM]
SelectivityMOP DOP KOP
EM-2 Tyr-Pro-Phe-Phe-NH2
c 0.79 ± 0.05 >1000 >1000 MOP-selective
1 Tyr-c[D-Lys-Phe-Phe-Asp]NH2
c 0.56 ± 0.03 279 ± 2.1 2.36 ± 0.15 KOP/MOP = 4.2
DOP/MOP = 498
2 Tyr-c[D-Orn-Phe-Phe-Asp]NH2 0.18 ± 0.01 >1000 4.26 ± 0.2 KOP/MOP = 23.7
3 Tyr-c[D-Dab-Phe-Phe-Asp]NH2 321 ± 29 >1000 >1000 MOP-selective
4 Tyr-c[D-Dap-Phe-Phe-Asp]NH2 0.51 ± 0.6 >1000 >1000 MOP-selective
5 Tyr-c[D-Lys-Phe-Asp]NH2 0.21 ± 0.015 461 ± 625 684 ± 59 KOP/MOP = 3257
DOP/MOP = 2195
a All values are expressed as means ± SEM for three independent experiments performed in duplicate. b Binding aﬃnity values were determined
by competitive displacement of the selective radioligands, [3H]DAMGO, [3H][Ile5,6]deltorphin-2 and [3H]nor-BNI for MOP, DOP and KOP
respectively. All values are expressed as means ± SEM for three independent experiments performed in duplicate. cData from ref. 15.
Fig. 1 LC-MS chromatograms recorded for crude products 2 (Fmoc
synthesis, panel A) and 2a (Boc synthesis, panel B). Insets in A present
fragments of MS spectra recorded for peaks at retention times 13.3 min
and 17.0 min and molecular structures of monomeric and dimeric forms
of peptide 2. Gray line: total ion chromatograms, black line: extracted
ion chromatograms (XIC) for m/z 686.33. The intensity scale of chroma-
tograms was adjusted to the present XIC as full scale signals.
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for calculating the intrinsic activity at the MOP, DOP, and KOP
receptor, respectively.
Results of this study demonstrated that peptides 1 and 2
behaved as mixed MOP/KOP receptor agonists with high
potency. Peptide 3 showed a similar low potency for MOP and
KOP receptors. Compounds 4 and 5 acted as selective and
highly potent full MOP agonists.
Correlation between ring size and receptor aﬃnity/selectivity
The comparison of the biological results for the cyclopeptides
1–5 reported in Table 1 highlighted an apparent correlation
between selectivity for the MOP receptor and the ring size
(Fig. 2). The largest cyclopeptide 1, Tyr-c[D-Lys-Phe-Phe-Asp]-
NH2, which includes the D-Lys connector and comprises 17
bonds in the ring, was an excellent MOP receptor ligand with
an IC50 of 0.56 nM, but showed a moderate selectivity over the
KOP receptor (KOP/MOP = 4.2). The introduction of D-Orn in
place of D-Lys in 2 reduced the ring size to 16 and increased
the MOP receptor aﬃnity (0.18 nM) and selectivity over KOP
(KOP/MOP = 23.7), while the 15-membered cyclopeptide 3 con-
taining D-Dab showed poor aﬃnity to the MOP receptor (IC50
in the 10−7 M range) but some selectivity, since it did not bind
to the other two receptors up to the 10−6 M concentration.
Finally, the 14-membered 4 showed a similar to 1 MOP aﬃnity
(0.51 nM) and was totally MOP receptor selective. Interestingly,
also peptide 5, Tyr-c[D-Lys-Phe-Asp]NH2, deprived of one Phe
residue, still maintained subnanomolar aﬃnity for the MOP
and high selectivity over DOP and KOP receptors, confirming
the optimality of the 14 membered ring size.
Previous experiments revealed that the parent cyclopeptide
1 (Tyr-c[D-Lys-Phe-Phe-Asp]NH2) adopted in a biomimetic
solvent system (8 : 2 DMSO-d6/H2O) a compact conformation,
not characterized by the secondary structure elements (Fig. 3,
1 in solution).29 On the other hand, molecular docking analy-
Table 3 Eﬀects of reference agonists and EM-2 derivatives at human recombinant opioid receptors coupled with calcium signaling via chimeric G
proteinsa
Peptide
MOP DOP KOP
pEC50 (CL95%) α ± sem pEC50 (CL95%) α ± sem pEC50 (CL95%) α ± sem
DPDPE Inactiveb 7.73 (7.40–8.07) 1.00 Inactiveb
Dynorphin A 6.67b (6.17–7.17) 0.83 ± 0.10b 7.73b (7.46–8.00) 0.99 ± 0.04b 8.46 (8.12–8.80) 1.00
EM-2 7.79 (7.53–8.04) 1.00 Inactive Inactive
1 8.69 (8.10–9.29) 0.83 ± 0.09 crc incomplete 8.18 (8.01–8.36) 1.00 ± 0.01
2 8.55 (8.36–8.74) 0.98 ± 0.04 6.45 (6.01–6.89) 0.54 ± 0.07* 8.14 (7.79–8.50) 1.01 ± 0.09
3 6.73 (6.47–6.98) 1.14 ± 0.09 crc incomplete 6.67 (6.42–6.92) 1.05 ± 0.09
4 8.14 (7.88–8.39) 0.95 ± 0.08 crc incomplete 6.18 (6.04–6.32) 0.57 ± 0.06*
5 8.56 (8.32–8.79) 1.01 ± 0.07 6.62 (6.23–7.01) 1.00 ± 0.13 crc incomplete
a Inactive means that the compound was inactive up to 1 µM. The crc incomplete means that maximal eﬀects could not be determined due to the
low potency of the compounds. DPDPE, dynorphin A and EM-2 were used as reference agonists for calculating the intrinsic activity at DOP, KOP
and MOP receptor respectively. bData are from ref. 22. *p < 0.05 was considered significant according to one way ANOVA followed by the
Dunnett’s test for multiple comparisons.
Fig. 2 Sketches of the structures of cyclopeptides 1–5 with the 17 to 14-membered rings.
Fig. 3 In solution and bioactive (i.e. MOP receptor-docked) structures
of 1; representative structures of 2–5 observed during a molecular
dynamics simulation in a 30 × 30 × 30 Å box of standard TIP3P water,
accounting for the experimentally observed MOP receptor aﬃnities and
selectivities (Table 1); bioactive structure of Jom-6. For clarity, only
amide NH and α-protons are shown.
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sis29 performed on our model of the human MOP receptor,
obtained by homology modelling30 subsequently validated
using the crystallographic structure disclosed in 2012,31
showed that this peptide adopted a diﬀerent conformation at
the MOP receptor. The conformations obtained from the
initial “blind docking” were optimized by combined quantum
mechanics/molecular mechanics computations using a flexible
receptor environment. The pose characterized by the best
binding energy showed CONH2 of Asp above the molecular
plane in a pseudo-axial position and the pseudo-axial phenyl
side chain of Phe4 below the molecular plane, while the
phenyl of Phe3 and Tyr residues occupied positions nearly
equatorial to the macrocycle ring (Fig. 3, 1 docking).
In order to find a rationale in the clear trend between the
ring-size and MOP receptor aﬃnity and selectivity, we analyzed
the conformational behavior of the cyclopeptides in solution
by MD simulation for 10 ns in a box of explicit water mole-
cules. Due to the flexibility of the D-Lys connector, during the
simulation of 1, the macrocycle adopted a variety of geome-
tries. Reasonably, this observation accounts for the ability of
the peptide to eﬃciently bind to the MOP receptor but with
modest selectivity. On the other hand, due to the presence of a
shorter D-Orn connector at position 2 of the sequence, the ana-
lysis of the trajectories of 2 revealed a lower conformational
freedom and the occurrence of compact structures character-
ized by a β-turn centered on Phe3–Phe4 at the positions i + 1
and i + 2, stabilized by an H-bond between D-LysCvO and
AspNH (Fig. 3, 2). Possibly, the increased selectivity of 2 for the
MOP can be correlated with the lower flexibility of the 16-mem-
bered ring. Interestingly, the β-turn geometry (Fig. 3, 2) nicely
reproduces the disposition of the pharmacophoric side chains
discussed above for 1 in its bioactive conformation.
A further reduction of the length of the connector was
achieved by the introduction of D-Dab in 3. The analysis of the
trajectories of the molecular dynamics simulations showed
that this shorter connector behaves as a more rigid spacer, pre-
venting the occurrence of the compact structures stabilized by
H-bonds as observed for 2. A representative, almost planar geo-
metry of 3 is shown in Fig. 3. This rigidity can explain the
highly reduced MOP receptor aﬃnity observed experimentally.
Finally, the conformational space accessible to the 14-mem-
bered cyclopeptides 4 and 5 was analyzed by MD. The cyclo-
peptide 4 containing D-Dap revealed a frequent formation of
the H-bonded β-turn secondary structure depicted in Fig. 3
which forces the pharmacophoric side chains to adopt the bio-
active conformation proposed for 1. This behaviour is not com-
pletely unexpected. Indeed, 4 contains two β-amino acid
residues, Asp and Dap, and it has been demonstrated that the
presence of β-residues in cyclotetrapeptides and cyclopenta-
peptides tends to favor the formation of the well-defined γ- or
β-turn structures in opposite regions of the cyclic
structure.32–34
As for cyclopeptide 5, which has the same sequence as 1
deprived of one Phe residue, the analysis of the trajectories of
MD showed a strong tendency to give a β-turn centered on
Phe-Asp, with an H-bond between the CvO of D-Lys and
D-LysNHε (Fig. 2). Fig. 3 shows the remarkable similarity of 5
to the bioactive conformation of the prototypic MOP receptor
agonist Jom-6.35 Due to the atypical sequence as compared to
compounds 1–4, in particular to the diﬀerent sequential posi-
tion and a 3D display of the CONH2 side chain, 5 might bind
to the MOP receptor taking advantage of other interactions.
Conclusions
A family of cyclic opioid peptides based on the structure of
EM-2 with varying ring size was synthesized. The ring for-
mation was achieved through an amide bond engaging the
side chain amino functions of dibasic amino acids in position
2 and the β-carboxy group of Asp in position 5. The ring size of
the cyclic analogs as well as the solid support used for the syn-
thesis determined the amount of dimeric side-products. In the
binding studies, confirmed by a calcium mobilization func-
tional test, the MOP selective or mixed MOP/KOP receptor
ligands were identified depending on the size of the ring. The
analysis of the biological results revealed a correlation between
selectivity for the MOP receptor and the ring size. A reduction
of the ring size increased MOP-selectivity. The MD calculations
allowed us to rationalize this observation on the basis of con-
formations accessible for the cyclic structures. The obtained
data highlighted the indirect role of changes in the size of the
macrocycle on inducing the backbone conformation, which, in
turn, oriented the side chains of the residues involved in the
receptor interaction. Obtaining MOP receptor selective and
non-selective analogs of EM-2 by introducing only small modi-
fications into the peptide sequence shows the complexity of a
binding phenomenon.
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